GC녹십자 그룹 내 세포·유전자치료제 전문 개발사 지씨셀(GC Cell)의 R&D pipeline, 연구개발, CDMO, 상업화/유통 역량 소개
近日,GC Cell宣布与Checkpoint Therapeutics(以下简称“Checkpoint”)达成战略合作,共同探索Checkpoint公司的cosibelimab(抗PD-L1抗体)与GC Cell的Immuncell-LC(自体T细胞疗法)进行联合治疗的潜力。 新闻稿指出,此次合作将首先在体外进行联合研究,以评...
Since signing a licensing agreement with Bifarma inSeptember 2024, GC Cell has been actively transferring the necessary technology to support local production and quality control. The six-month program, conducted at GC Cell’s headquarters, is on track to enable Bifarma to launch Immunc...
GC Cell said Wednesday that it has officially begun the technology transfer process for its immunotherapy, Immuncell-LC, in collaboration with PT Bifarma Adiluhung, the Indonesian subsidiary of Southeast Asia’s largest pharmaceutical company, PT Kalbe Farma Tbk. The technology transfer follows a lic...
近日,韩国GC绿十字公司宣布收购总部位于美国纽瓦克细胞基因治疗CDMO公司BioCentriq的100%股份,交易金额为7300万美元。其中GC母公司将出资5300万美元,子公司GC Cell出资2000万美元。 绿十字集团成立于1967年是韩国主要生物制药企业,曾成功开发乙肝疫苗、水痘疫苗等...
cancer — now armed with the power of AI. This initiative is part of GC Cell's broader strategy to integrate digital & AI technology into all aspects of healthcare, from research and development to patient care. I believe it will prepare our company fo...
近日,美国纽约洛克菲勒大学分子免疫学实验室的研究团队在杂志《Cell》上发表了研究型的文章“Continuous germinal center invasion contributes to the diversity of the immune response”(持续的生发中心侵袭有助于免疫反应的多样性)。他们描述了谱系追踪实验,其中在GC反应期间追踪多克隆幼稚B细胞的命运。
申请/注册号:28784174申请日期:2018-01-18国际分类:第05类-医药商标申请人:牡丹江霖润药用辅料有限责任公司办理/代理机构:牡丹江荣达知识产权代理有限公司 GCELL商标注册申请 申请/注册号:15105678申请日期:2014-08-06国际分类:第05类-医药商标申请人:北京九强生物技术股份有限公司办理/代理机构:北京戈程知识产权代理有...
Alternative Names:Autoimmune disease therapy - GC Cell; Dendritic cell therapy - GC Cell; Regulatory T cell therapy - GC Cell; Stem cell therapy - GC Cell Latest Information Update:12 Sep 2019 Price : €55* Note: Adis is an information provider.We do not sell or distribute actual drugs. ...
▲图源“JUN CELL”,版权归原作者所有,如无意中侵犯了知识产权,请联系我们删除 国内的TILs疗法是在美国的肿瘤浸润淋巴细胞(TIL)疗法基础上经过改良,提升其克服肿瘤微环境和增加自我扩增的能力,在前期的概念验证临床研究中已取得了非常积极的疗效和安全性验证,目前已获得批准正式开展人体临床试验!